Prostate carcinoma response to cytotoxic therapy: In vivo resistance

In Vivo

Volumn 11, Issue 6, 1997, Pages 453-461

  Teicher, Beverly A ^a,b   Kakeji, Yoshihiko ^a   Ara, Gulshan ^a   Herbst, Roy S ^a   Northey, David ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Drug resistance; Prostate carcinoma; Transforming growth factor

Indexed keywords

ANDROGEN; CYCLOPHOSPHAMIDE DERIVATIVE; CYTOTOXIC AGENT; DOXORUBICIN; MELPHALAN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MONOLAYER CULTURE; NONHUMAN; NUDE MOUSE; PROSTATE CARCINOMA; SCID MOUSE; XENOGRAFT;

EID: 0031418669     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Bubley G and Ball S: Treatment of androgen-independent prostate cancer. The Oncologist 1: 30-35, 1996.
2. Mani S and Vogelzang N: Is "Off-protocol" chemotherapy for androgenindepenent carcinoma of prostate warranted? Prostate Cancer 10: 749-768, 1996.
3. Bubley G and Balk S: Treatment of metastatic prostate cancer. Prostate Cance 10: 713-726, 1996.
4. Teicher B, Maehara Y, Kakeji Y, Ara G, Keyes S, Wong J and Herbst R: Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Int J Cancer, submitted: 1996.
5. Teicher BA, Holden SA, Ara G and Chen G: Transforming growth factor-β in in vivo resistance. Cancer Chemother Pharmacol 37: 601-609, 1996.
6. Teicher BA, Chatterjee D, Liu J-T, Holden SA and Ara G: Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother Pharmacol 32: 315-319, 1993.
7. Chatterjee D, Liu JT, Northey D and Teicher BA: Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother. Pharmacol 35: 423-431, 1995.
8. Muir GH, Butta A, Shearer RJ, Fisher C, Dearnaley DP, Flanders KC, Sporn MB and Colletta AA: Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 69: 130-134, 1994.
9. Herman ME and Katzenellenbogen BS: Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867-5874, 1994.
10. McBrlde WH: Cytokine cascades in late normal tissue radiation responses. Int J Radiat Oncol Biol Phys 33: 233-234, 1995.
11. Rubin P, Johnston CJ, Williams JP, McDonald S and Finkelstein JN: A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33: 99-109, 1995.
12. Merzak A, McCrea S, Koocheckpour S and Pilkington G: Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor β1 Brit J Cancer 70: 199-203, 1994.
13. Anscher MS and Jirtle RL: Role of transforming growth factor-β and hepatocyte growth factor in late normal tissue effects of radiation. Radiat Oncol Invest 1: 305-313, 1994.
14. Anscher M, Murase T, Prescott D, Marks L, Reisenbichler H, Bentel G, Spencer D, Sherouse G and Jirtle R: Changes in plasma TGF-β levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 30: 671-676, 1994.
15. Anscher MS, Peters WP, Reisenbichler H, Petros WP and Jirtle RL: Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New Eng J Med 328: 1592-1598, 1993.
16. Williams R, Stapleton A, Yang G, Truong L, Rogers E, Timme T, Wheeler T, Scardino P and Thompson T: Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clinical Cancer Research 2: 635-640, 1996.
17. Teicher B, Bump E, Palayoor S, Northey D and Coleman C: Signal transduction inhibitors as modifiers of radition therapy in human prostate carcinoma xenografts. Rad Oncol Invst, in press: 1997.
18. Veldscholte J, Berrevoets C and Mulder E: Studies on the Human Prostatic Cancer Cell Line LNCaP. J Steroid Biochem Molec Biol 49: 341-346, 1994.
19. Hsieh I, Wu H, Gleave M, vonEschenbach A and Chung L: Autocrine Regulation of Prostate-specific Antigen Gene Expression in a Human Prostatic Cancer (LNCaP) Subline. Cancer Res 53: 2852-2857, 1993.
20. Hentuu P and Vihko P: Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53: 1051-1058, 1993.
21. Berrevoets C, Veldscholte J and Mulder E: Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J Steroid Biochem Molec Biol 46: 731-736, 1993.
22. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA and Mulder E: Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31(8): 2393-2399, 1992.
23. Olea N, Sakabe K, Soto A and Sonnenschein C: The Proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126: 1457-1463, 1990.
24. Veldscholte J, Voorhorst-Ogink M, Bolt-deVries J, vanRooij H, Trapman J and Mulder E: Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochem Biophys Acta 1052: 187-194, 1990.
25. Veldscholte J, Ris-Stalpers C, Kuiper J, Jenster G, Berrevoets C, Claassen E, vanRooij H, Chapman J, Brinkmann A and Mulder E: A Mutation in Ligand Binding Domain of the Androgen Receptor of Human LNCaP cells affects Steroid Binding Characteristics and Response to anti-androgens. Biochem Biophys Res Comm 173: 534-540, 1990.
26. Wilding G, Chen M and Gelman E: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. The Prostate 14: 103-115, 1989.
27. Teicher BA, Holden SA, Herman TS, Alvarez Sotomayor E, Khandekar V, Rosbe KW, Brann T-W, Korbut TT and Frei III E: Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II) Int J Cancer 47: 252-260, 1991.
28. Wright J Phosphoramine and oxazaphosphorine mustards. In: B Teicher (eds.), Cancer Therapeutics: Experimetal and Clinical Agents, pp. 23-79. Totowa NJ: Humana Press, 1996.
29. Yagoda A and Petrylak D: Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. Cancer 71: 1098-1109, 1993.
30. Torti F, Aston D and Lum B: Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1: 477-482, 1983.
31. Fossa S, Urnes T and Kaalhus O: Weekly low-dose adriamycin in hormone resistant metastatic cancer of the prostate. Scand J Urol Nephrol 21: 13-16, 1987.
32. Scher H, Yagoda A and Watson R: Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131: 1099-1102, 1984.
33. Osbourne C, Drelichman A and VanHoff D: Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 67: 1133-1135, 1983.
34. Moore M, Osoba D and Murphy K: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12: 689-694, 1994.
35. Smith D, Vogelzang N and Goldberg J: High-dose cyclophosphamide with GM-CSF in hormone-refractory prostatic carcinoma. Proc Am soc Clin Oncol 11:212a, 1992.
36. vonRoemeling R, Fisher H and Horton J: Daily oral cyclophosphamide is effective in hormone-refractory prostate cancer: a phase I/II pilot trial. Proc Am Soc Clin Oncol 11: 213a, 1992.
37. Eisenberger M and Abrams J: Chemotherapy for prostatic carcinoma. Semin Urol 6: 303-310, 1988.
38. Reyno L, Eroin M, Eisenberger M, Sinibaldi V, Zuhowski E and Sridhara R: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13: 2187-2195, 1995.
39. Stein C: Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53: 239-258, 1995.
40. Kelley W, Curley T and Liebertz C: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13: 2208-2213, 1995.
41. Eisenberger M, Sinbaldi V and Reyno L: Phase I and clinical evaluation of a pharmacologically fixed dosing scheme for suramin. J Clin Oncol 13: 2174-2186, 1995.
42. Koch P, Bayer G and McGovern J: Continuous infusion 5-FU and weekly doxorubicin for hormone-resistant prostate cancer. Proc Am Soc Clin Oncol; 11: 207a, 1992.
43. Pienta K, Redman B and Hussain M: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005-2012, 1994.
44. Hudes G, Greenberg R and Krigel R: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory adenocarcinoma. J Clin Oncol 10: 1754-1761, 1992.
45. Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M and Lee C: Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 56: 44-48, 1996.
46. Franzen P, Ichijo H and Miyazono K: Different signals mediate transforming growth factor-β1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp Cell Res 207:1-7, 1993.
47. Steiner M and Barrack E: Transfroming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinology 6: 15-25, 1992.
48. Steiner M, Zhou Z-Z, Tonb D and Barrack E: Expression of transforming growth factor-B1 in prostate cancer. Endocrinology 135: 2240-2247, 1994.
49. Morton D and Barrack E: Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596-2602, 1995.
50. Sehgal I, Baley P and Thompson T: Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56: 3359-3365, 1996.
51. Hsing A, Kadomatsu K, Bonham M and Danielpour D: Regulation of apoptosis induced by transforming growth factor-β1 in nontumorigenic and tumorigenic rat prostatic epithelial cell lines. Cancer Res 56: 5146-5149, 1996.
52. Kim I, Zelner D, Sensibar J, Ahn H-J, Park L, Kim J-H and Lee C: Modulation of Sensitivity to Transforming Growth Factor β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCap Cells by Dihydrotestosterone. Exp Cell Res 222: 103-110, 1996.
53. Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A and Frei III E: Alkylating agents: in vitro studies of cross-resistance patterns. Cancer Res 46: 4379-4383, 1986.
54. Teicher BA and Frei III E: Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother. Pharmacol 21: 292-298, 1988.
55. Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD and Frei III E: Characterization of a human squamous carcinoma cell line resistant to cis-diammine-dichloroplatinum(II). Cancer Res 47: 388-393, 1987.
56. Teicher BA, Herman T S, Holden S A, Wang Y, Pfeffer M R, Crawford J M and Frei III E: Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:. 1457-1461, 1990.
57. Teicher BA, Northey D, Yuan J and Frei III E: High-dose therapy/stem cell support: comparison.of mice and humans. Int J Cancer 65: 695-699, 1996.